Bardet-Biedl Syndrome (BBS) is a rare genetic ciliopathy characterized by hyperphagia and early-onset obesity. Clinicians recently introduced setmelanotide, a melanocortin-4-receptor (MC4R) agonist, as a breakthrough therapy for chronic weight management in these patients. While the drug effectively reduces hunger scores, it frequently leads to noticeable cutaneous changes. Physicians must prioritize setmelanotide dermatologic screening because hyperpigmentation represents the most prevalent side effect of this treatment.

Importance of Setmelanotide Dermatologic Screening

Clinical trials indicate that approximately 67% to 83% of patients experience generalized or focal skin darkening. This phenomenon occurs because MC4R activation directly stimulates melanocytes. Consequently, patients often notice a deeper skin tone within the first few weeks of starting therapy. Moreover, clinicians have observed the development of new melanocytic nevi and the darkening of pre-existing moles in a significant portion of the treated population. These changes usually reverse upon discontinuation, yet they necessitate vigilant monitoring to distinguish benign drug-induced changes from potential malignancy.

Current Guidelines for Skin Monitoring

Although universal guidelines remain in development, experts emphasize a proactive approach to patient safety. Physicians should perform a comprehensive full-body skin examination before initiating setmelanotide therapy. Furthermore, patients require annual dermatologic assessments to track alterations in existing lesions or the appearance of new ones. If a patient notices rapid changes in the size or color of a mole, they must seek immediate evaluation. Therefore, integrated care between endocrinologists and dermatologists ensures safer long-term obesity management for the BBS community.

Frequently Asked Questions

How common is skin darkening with setmelanotide?

Hyperpigmentation is the most common side effect, affecting the majority of patients. It typically presents as a generalized darkening of the skin or darkening of specific areas like joints and existing scars.

Are the skin changes permanent?

Current clinical data suggests that increased skin pigmentation and the darkening of moles are generally reversible once the patient stops taking the medication.

What should I look for during a skin check?

Patients and providers should monitor for new moles, changes in the symmetry or borders of existing nevi, and any significant increase in the size or darkness of pigmented spots.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Smith S et al. Setmelanotide in Bardet-Biedl Syndrome: A Case Report. Pediatr Dermatol. 2026 Apr 17. doi: 10.1111/pde.70186. PMID: 41994885.

StatPearls. Setmelanotide. NCBI Bookshelf. Updated July 2, 2023.

FDA. IMCIVREE (setmelanotide) prescribing information. Updated June 2022.